证券代码：600351 证券简称：亚宝药业 公告编号：2025-026 亚宝药业集团股份有限公司 关于合伙企业份额转让给全资子公司暨退伙的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、投资合伙企业情况概述 1、2020年12月18日，亚宝药业集团股份有限公司（以下简称"公司"或"亚 宝药业"）与浙江华方资产管理有限公司（以下简称"华方资产"）签署了《武 汉健民资本合伙企业（有限合伙）合伙权益转让协议》，公司以0元人民币受让 华方资产持有的武汉健民资本合伙企业（有限合伙）（以下简称"健民资本"） 40.68%的财产份额。健民资本全体合伙人认缴出资总额为29,500万元，其中：华 方资产认缴出资13,350万元，实缴出资0元。转让完成后，公司成为健民资本新 的有限合伙人，持有健民资本40.68%的份额，对应认缴出资额12,000万元。具体 内容详见公司于2020年12月19日在上海证券交易所、上海证券报及中国证券报上 披露的《亚宝药业集团股份有限公司关于受让武汉健民资本合伙企业（有限合伙） 财产份额的公告》（公告编号： ...

Core Viewpoint - The company is optimizing its external investments and improving asset operation efficiency through the transfer of its stake in Wuhan Jianmin Capital Partnership [1] Group 1 - The company announced the transfer of its 50 million yuan stake in Wuhan Jianmin Capital Partnership for 49.0235 million yuan to its wholly-owned subsidiary, Yabao Ailegao Biopharmaceutical Co., Ltd [1] - The company agreed to withdraw from a 70 million yuan stake for 68.633 million yuan [1] - After the transaction, the total capital contribution of all partners in Jianmin Capital will decrease to 205 million yuan, and the company will hold a 24.44% stake in Jianmin Capital through its subsidiary [1]

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

Group 1 - The company has approved a share repurchase plan with a total funding amount between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 6.95 per share [1][2] - The repurchase will be conducted through centralized bidding and aims to cancel the repurchased shares, thereby reducing the registered capital of the company [1] - The repurchase period is set for a maximum of 6 months from the date of the shareholders' meeting approval [1] Group 2 - The company has obtained a loan commitment letter from the Bank of China, with a maximum loan amount of RMB 90 million and a loan term not exceeding 3 years [2] - The loan is intended to support the company's share repurchase activities [2] - The actual repurchase amount will be determined based on the market conditions and the availability of funds at the end of the repurchase period [2]

亚宝药业集团股份有限公司 关于取得金融机构股票回购贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份方案的基本情况 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于 人民币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民 币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股 东大会审议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资 金及自筹资金。具体内容详见公司于 2025 年 5 月 17 日在上海证券交易所网站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团 股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、取得金融机构股票回购贷款承诺函的情况 近日，公司取得中国 ...

亚宝药业（600351）公告，公司近日取得中国银行股份有限公司运城市分行出具的《贷款承诺函》，承 诺贷款金额最高不超过9000万元，贷款期限不超过3年，贷款用途为股票回购。此前，公司于2025年5月 16日召开的2024年年度股东大会审议通过了以集中竞价方式回购股份的议案，回购资金总额不低于0.5 亿元且不超过1亿元，回购价格不超过6.95元/股，回购用途为全部予以注销并减少公司注册资本，回购 期限为不超过6个月，资金来源为公司自有资金及自筹资金。 ...

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 9, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted via video live streaming and online interaction at the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions from May 30, 2025, to June 6, 2025, through the Roadshow Center website or via the company's email [3] Group 2 - Key personnel attending the briefing include the Chairman, Secretary of the Board, Chief Financial Officer, and an Independent Director [2] - After the briefing, investors can view the main content and details of the event on the Shanghai Stock Exchange Roadshow Center [3]

重要内容提示： 投资者可于 2025 年 05 月 30 日 （星期五） 至 06 月 06 日 （星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wangyu@yabaoyaoye.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 亚宝药业集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发 布公司 2024 年年度报告和 2025 年第一季度报告，便于广大投资者更全面深入地 了解公司 2024 年度及 2025 年第一季度的经营成果、财务状况，公司计划于 2025 年 06 月 09 日 （星期一） 15:00-17:00 举行 2024 年度暨 2025 年第一季度业绩 说明会，就投资者关心的问题进行交流。 证券代码：600351 证券简称：亚宝药业 公告编号：2025-024 亚宝药业集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二） 会议召开地点：上证路 ...

Core Points - The company announced a cash dividend of 0.3 CNY per share for its A shares, totaling approximately 210 million CNY to be distributed to shareholders [1][2][3] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 16, 2025 [1][2] - Key dates for the dividend distribution include the record date on May 29, 2025, and the ex-dividend date on May 30, 2025 [2][3] Dividend Distribution Details - The total share capital of the company is 700,000,046 shares, and the cash dividend will be distributed based on this total [1][2] - For individual shareholders and securities investment funds, no income tax will be withheld at the time of dividend distribution; tax will be calculated based on the holding period when shares are sold [3][4] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of 0.27 CNY per share [3][4] - For Hong Kong Stock Exchange investors, the same 10% withholding tax applies, leading to a net dividend of 0.27 CNY per share [3][4] - Resident corporate shareholders are responsible for their own tax payments, receiving the full dividend of 0.3 CNY per share [3][4]